ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1916

Healthcare Disparities and Clinical Outcomes in Cardiac Sarcoidosis. a Retrospective Cohort Study
Abstract Number: 1917

Access to Rheumatology Care near Indian Health Service Hospitals for American Indian Communities
Abstract Number: 1918

Exploring the Childhood Opportunity Index and Distance to Care in a Cohort of Children with Rheumatic Disease
Abstract Number: 1919

Patient-reported Social Risk Factor Screening Among Rheumatology Outpatients
Abstract Number: 1920

Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis
Abstract Number: 1921

Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
Abstract Number: 1922

Insights into Rheumatology Practice in Uganda
Abstract Number: 1923

Social Determinants of Health Documentation and Prevalence Among Rheumatology Patients Seen in a Southern Medical Center
Abstract Number: 1924

Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials
Abstract Number: 1925

Use of Geocoded Social Deprivation Indices to Understand Health Disparities in Pediatric Rheumatology
Abstract Number: 1926

Race/ethnicity Is Associated with Disease Severity in Pediatric Patients with ANCA-associated Vasculitis Hospitalized in the United States
Abstract Number: 1927

Ethnic and Racial Minorities in Clinical Trials for Autoimmune Connective Tissue Disease Therapeutic Agents
Abstract Number: 1928

Utilization of Rapid Telehealth Visits by Advanced Practice Providers for New Patients Referred to a Large Academic Practice with Low Suspicion for Rheumatologic Disease
Abstract Number: 1929

Use of Digital Health Tools for Health Promotion Among Individuals with Rheumatologic Diseases in the United States
Abstract Number: 1930

Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].